HCAT Health Catalyst
- 6.340
- -0.080-1.25%
Health Catalyst News
Health Catalyst(HCAT.US) Officer Sells US$19,281.09 in Common Stock
$Health Catalyst(HCAT.US)$ Officer Alger Jason sold 2,823 shares of common stock on Jun 12, 2024 at an average price of $6.83 for a total value of $19,281.09.Source: Announcement What is statement of
Health Catalyst(HCAT.US) Officer Sells US$16,017.96 in Common Stock
$Health Catalyst(HCAT.US)$ Officer Landry Benjamin sold 2,387 shares of common stock on Jun 6, 2024 at an average price of $6.7105 for a total value of $16,017.96.Source: Announcement What is statemen
Health Catalyst(HCAT.US) Officer Sells US$49,008 in Common Stock
$Health Catalyst(HCAT.US)$ Officer Freeman Kevin Lee sold 7,500 shares of common stock on Jun 11, 2024 at an average price of $6.5344 for a total value of $49,008.Source: Announcement What is statemen
Health Catalyst(HCAT.US) Officer Sells US$80,064.14 in Common Stock
$Health Catalyst(HCAT.US)$ Officer LeSueur Daniel sold 11,923 shares of common stock on Jun 6, 2024 at an average price of $6.7151 for a total value of $80,064.14.Source: Announcement What is statemen
Wells Fargo Maintains Health Catalyst(HCAT.US) With Buy Rating, Maintains Target Price $13
Wells Fargo analyst Stan Berenshteyn maintains $Health Catalyst(HCAT.US)$ with a buy rating, and maintains the target price at $13.According to TipRanks data, the analyst has a success rate of 55.8% a
Health Catalyst Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Throughout the last three months, 4 analysts have evaluated Health Catalyst (NASDAQ:HCAT), offering a diverse set of opinions from bullish to bearish.The table below summarizes their recent ratings, s
Health Catalyst Is Maintained at Overweight by Piper Sandler
Health Catalyst Is Maintained at Overweight by Piper Sandler
Express News | Health Catalyst Acquires Oncology-Focused Health Technology Company Carevive
Piper Sandler Maintains Health Catalyst(HCAT.US) With Buy Rating, Cuts Target Price to $14
Piper Sandler analyst Jessica Tassan maintains $Health Catalyst(HCAT.US)$ with a buy rating, and adjusts the target price from $15 to $14.According to TipRanks data, the analyst has a success rate of
Health Catalyst to Participate in Upcoming Investor Conferences
SALT LAKE CITY, May 30, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ((", Health Catalyst", , NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today
Why Health Catalyst (HCAT) Might Be Well Poised for a Surge
Wall Street Analysts See a 75.19% Upside in Health Catalyst (HCAT): Can the Stock Really Move This High?
A Look Back at Data Analytics Stocks' Q1 Earnings: Health Catalyst (NASDAQ:HCAT) Vs The Rest Of The Pack
Peeling Back The Layers: Exploring Health Catalyst Through Analyst Insights
8 analysts have expressed a variety of opinions on Health Catalyst (NASDAQ:HCAT) over the past quarter, offering a diverse set of opinions from bullish to bearish.The following table summarizes their
Health Catalyst Is Maintained at Buy by Canaccord Genuity
Health Catalyst Is Maintained at Buy by Canaccord Genuity
Express News | Canaccord Genuity Maintains Buy on Health Catalyst, Maintains $11 Price Target
Health Catalyst Unveils Next-Generation Data and Analytics Ecosystem Built for Healthcare, Health Catalyst Ignite
Health Catalyst(HCAT.US) Officer Sells US$14,462 in Common Stock
$Health Catalyst(HCAT.US)$ Officer Llewelyn Linda sold 2,066 shares of common stock on May 15, 2024 at an average price of $7 for a total value of $14,462.Source: Announcement What is statement of cha
Express News | Health Catalyst Inc : Jefferies Cuts Target Price to $10 From $12
Analysts Have Conflicting Sentiments on These Healthcare Companies: Curis (CRIS), Health Catalyst (HCAT) and Innate Pharma SA (OtherIPHYF)
Analysis
Price Target
No Data
